• patient with medicine

Pharmacovigilance

Medicines and  vaccines have transformed the prevention and treatment of diseases over time. In addition to their benefits, they can have side effects, some of which may be undesirable and/or unexpected. Pharmacovigilance is the science and the activities related to the detection, assessment, understanding, and prevention of adverse effects or any other medicine or vaccine related problem.

The  pharmacovigilance seeks to ensure that the benefit-risk ratio remains favorable throughout the life cycle of amedicine , i.e., from the time it is authorized until it is withdrawn from the market, or its production is discontinued. Pharmacovigilance comprises various activities involving the management and analysis of public health risk to ensure the rational use of medicines. Risk identification, quantification, and assessment associated with the use of medicines can avoid or minimize harm to patients and can prompt the adoption of necessary measures, including any necessary regulatory actions.

Objectives of pharmacovigilance

  • Improve patient care and safety in relation to the use of medicines and all medical interventions
  • Improve public health and safety in relation to the use of medicines;
  • Detect problems related to the use of medicines and communicate findings in a timely manner
  • Contribute in the assessment of the benefit-risk ratio, effectiveness, and risk of medicines, leading to the prevention of harm and maximization of benefits
  • Encourage the safe, rational, and more effective (including cost-effective) use of medicines
  • Promote the understanding, education and training of pharmacovigilance and its effective communication to the public.

Pharmacovigilance Programs in some countries of The Americas
 

Indicadores GBT

Link to the official sites of the regulatory agencies of the main countries of the region.

MORE INFORMATION

The Regional Pharmacovigilance Network of the Americas
 

red puntos focales

The network is to promotes the exchange of information, resources and experiences between National Regulatory Authorities of the Americas, to strengthen the vigilance of medicine safety in the Region.

Caribbean Sub-regional Network - VigiCarib

VigiCarib is a voluntary sub-regional system that the Member States of the Caribbean Community (CARICOM) use to report suspected adverse drug reactions (ADRs) and substandard or counterfeit medical products..

MORE INFORMATION

The WHO global benchmarking tool (GBT)
 

Indicadores GBT

Tool for evaluation of national regulatory systems is the primary means to objectively evaluate national regulatory systems for medical products.

MORE INFORMATION

PAHO Response

  • Promotes guidelines and recommendations on the safe, rational, and more effective use of medicines.
  • Provides technical cooperation with national medicine safety surveillance systems and encourages work through global networks to promote pharmacovigilance in countries.
  • Establishes and maintains links with WHO collaborating centers to provide technical support on pharmacovigilance to countries.
  • Encourage training to develop and strengthen the capacity of national vigilance systems for medicine safety.
  • Promotes studies, method development and implementation of innovative tools to generate new evidence on medicine safety.

    Based on CSP30/10 "Policy for the strengthening of national regulatory systems of medicines and other health technologies", the regulatory strengthening approach addresses the following points:

  • Governance and stewardship

  • Strengthening of systems,capacities and operations

  • Convergence

  • Regulatory framework. GBT

From Pharmacovigilance the following actions contribute to this construction:

Active Pharmacovigilance

Farmacovigilancia facilitada activa

The active pharmacovigilance consist of the aplication of procedures based on systematic and detailed collection of data on harmful effects assumed to be induced by medicines in certain population groups.
MORE INFORMATION

Risk Management Plans and Periodic Safety Reports

Informes periodicos

Documents that the national drug regulatory authority or other competent authority of a country requires from the marketing authorization holder of a medicine or vaccine.
 

Pharmacovigilance of COVID-19

Vaccines

 

Vacunas

MORE INFORMATION

 

Medicines

 

Medicamentos

MORE INFORMATION

Sub-group for COVID-19 vaccines regulatory support

Subgrupo

This sub-group provides technical support in the regulatory processes for the adequate introduction and safety surveillance of COVID-19 vaccines and related therapies.
 

MORE INFORMATION

Recursos

Pharmacovigilance for COVID-19 vaccines dashboard

tablero fvg

Regional vaccination dashboard

Tablero ops

Periodic Update Reports on AEFI – COVID-19 vaccines

esavi

Herramientas

Support tool for causality assessment

ESAVI

Tools for the causality assessment of adverse events following immunization (AEFI)

MORE INFORMATION

VigiMobile
 

Med Safety App

Is a new offline app to report AEFI

Computer bridges

Puente Informático

Computer bridges are customized software programs (developed for different structures and data-capture formats), allowing the user to transform data associated with reports of adverse events to an appropriate standard for electronic case reporting

MORE INFORMATION

Pharmacovigilance toolkit

Toolbox with access to the most important resources used in pharmacovigilance

LINK TO THE TOOLKIT

Trainings

CVSP


Basic Self-Learning Course in Pharmacovigilance PAHO/WHO
 

curso de farmacovigilancia

 

:

To present and promote the understanding of the basic concepts in post-authorization safety surveillance of medicines and vaccines to contribute to the strengthening of human resources in the national pharmacovigilance systems.

Completed editions:

  • Cohort 2017
  • Cohort 2021

 

OMS

WHO provides Pharmacovigilance courses and trainings

COURSE LIST

Uppsala Monitoring Centre

Uppsala Monitoring Centre (UMC) provides Pharmacovigilance courses and trainings

COURSE LIST

Documents

Communication Materials

All

Mandates and Strategies

All

More information